Form 8-K INTEGRA LIFESCIENCES For: Apr 13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 13, 2015

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact name of Registrant as specified in its charter)

311 Enterprise Drive

Plainsboro, NJ 08536

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 275-0500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

As previously disclosed, Integra LifeSciences Holdings Corporation (the “Company” or “Integra”) announced plans in November 2014 to spin off its spine business to Integra stockholders on a tax-free basis (the “spin-off”). The spin-off will create a new publicly traded company called SeaSpine Holdings Corporation (“SeaSpine”). In connection with the announcement of the spin-off, the Company also announced its determination to realign its segment presentation. Beginning in the First quarter of 2015, the Company will report in three segments, as follows:

The Company’s new Specialty Surgical Solutions segment will consist of its former U.S. Neurosurgery and U.S. Instruments segment, as well as a portion of the International segment. Products and services included in the Specialty Surgical Solutions segment will be dural repair, precision tools & instruments, tissue ablation, and services and repair.

Orthopedic & Tissue Technologies will consist of the former U.S. Extremities segment and the portion of the former U.S. Spine and Other segments that will not be included in SeaSpine, and a portion of the former International segment. The Company’s products and services included in the new Orthopedic & Tissue Technologies segment will be regenerative technologies, lower extremities, upper extremities, and private label.

The Company’s Spine segment will consist of the majority of the former U.S. Spine and Other business that, in connection with the spin-off, will be transferred to SeaSpine, as well as a portion of the former International segment. Upon completion of the spin-off, Integra will update its segment presentation to reflect its two remaining segments.

The Company has furnished with this report a presentation contained in Exhibit 99.1 including unaudited segment revenue information reflecting the Company’s new reportable segments for the year ended December 31, 2014 and for each of the quarterly periods in the years ended December 31, 2014 and 2013.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Exchange Act or the Securities Act of 1933, as amended.

99.1    Historical Segment Revenue Information (unaudited)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

Exhibit 99.1 Historical Segment Revenue: New Segments 2012 – 2014

New Reporting Segments Information 2 In November 2014, Integra announced the strategic decision to spin off the orthobiologics and spinal fusion hardware business into a separate, publicly traded company called SeaSpine Holdings Corporation.  Integra management believes that a stand-alone SeaSpine will be better positioned to compete by allowing the new management team to focus and dedicate resources to drive growth, and that this form of separation should enable both Integra and SeaSpine to grow faster separately than they would together. As part of the same announcement, Integra announced that it would realign its existing five business segments into three new segments, each representing global organizations.  As of January 1, 2015, the three new segments are called Specialty Surgical Solutions, Orthopedic & Tissue Technologies, and Spine. Specialty Surgical Solutions consists of our prior U.S. Neurosurgery and U.S. Instruments segments as well as a portion of the International segment.  Orthopedic & Tissue Technologies is comprised of the former U.S. Extremities segment and a portion of both the U.S. Spine and Other and International segments.  The third segment contains the majority of the former U.S. Spine and Other business that will be included in the newly created SeaSpine, which, until the spin-off, we will refer to as our Spine segment. The unaudited historical revenue information for these segments is provided in the following slides.  This new segment breakout aligns with the way in which we manage the company.  Going forward, our commentary and guidance will correspond to these new segments until the completion of the spin-off, at which point our business will contain only the Specialty Surgical Solutions and Orthopedics & Tissue Technologies segments.

Annual Revenue: 2012 – 2014 3 UNAUDITED ($ in Thousands) Global Segment Revenues: In thousands 2012 2013 2014 Specialty Surgical Solutions 464,169 $       463,296 $ 554,872 $ U.S. 334,168          332,781    399,538    International 130,001          130,515    155,334    Orthopedics & Tissue Technologies 218,972          225,737    235,539    U.S. 174,256          180,664    190,932    International 44,716            45,073       44,607       Spine 147,730          147,181    137,894    U.S. 134,406          129,249    123,570    International 13,324            17,932       14,324       Total Revenue 830,871 $       836,214 $ 928,305 $ U.S. 642,830          642,694    714,040    International 188,041          193,520    214,265

Quarterly Revenue: 2013 4 UNAUDITED ($ in Thousands) Global Segment Revenues: In thousands Q1 13 Q2 13 Q3 13 Q4 13 2013 Specialty Surgical Solutions 106,433 $ 114,598 $ 120,780 $ 121,485 $ 463,296 $ U.S. 76,161       81,905       87,383       87,332       332,781    International 30,272       32,693       33,397       34,153       130,515    Orthopedics & Tissue Technologies 54,193       54,574       56,769       60,201       225,737    U.S. 42,162       43,138       47,793       47,571       180,664    International 12,031       11,436       8,976         12,630       45,073       Spine 36,026       36,375       35,697       39,083       147,181    U.S. 31,696       32,123       31,379       34,051       129,249    International 4,330         4,252         4,318         5,032         17,932       Total Revenue 196,652 $ 205,547 $ 213,246 $ 220,769 $ 836,214 $ U.S. 150,019    157,166    166,555    168,954    642,694    International 46,633       48,381       46,691       51,815       193,520

Quarterly Revenue: 2014 5 UNAUDITED ($ in Thousands) Global Segment Revenues: In thousands Q1 14 Q2 14 Q3 14 Q4 14 2014 Specialty Surgical Solutions 127,195 $ 137,516 $ 137,499 $ 152,662 $ 554,872 $ U.S. 90,447       99,379       101,403    108,309    399,538    International 36,748       38,137       36,096       44,353       155,334    Orthopedics & Tissue Technologies 54,589       57,954       58,616       64,380       235,539    U.S. 43,280       47,079       48,056       52,517       190,932    International 11,309       10,875       10,560       11,863       44,607       Spine 33,275       35,881       33,604       35,134       137,894    U.S. 29,655       32,348       30,642       30,925       123,570    International 3,620         3,533         2,962         4,209         14,324       Total Revenue 215,059 $ 231,351 $ 229,719 $ 252,176 $ 928,305 $ U.S. 163,382    178,806    180,101    191,751    714,040    International 51,677       52,545       49,618       60,425       214,265

Integra Historic Revenue Reporting Segments 6 U.S. Neurosurgery (26%) U.S. Instruments (17%) U.S. Extremities (15%) U.S. Spine & Other (19%) International (23%) (%) Shows percentages of 2014 Revenues Integra Prior Segments (% of Total 2014 Revenue)

Integra New Revenue Reporting Segments 7 U.S. Neurosurgery (26%) U.S. Instruments (17%) U.S. Extremities (15%) U.S. Spine & Other (19%) International (23%) (%) Shows percentages of 2014 Revenues Orthopedics & Tissue Technologies (25%) Specialty Surgical Solutions (60%) Spine (15%) Dural Repair Key Franchises: Precision Tools & Instruments Tissue Ablation Neuro Critical Care Services and Repair Key Franchises: Regenerative Technologies Lower Extremities Upper Extremities Private Label

You May Also Be Interested In

• Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
• Groupe SEB: First-quarter 2024 Sales and Financial Data
• REGENT Advances the Future of Coastal Transportation in Abu Dhabi